Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenmei Pian
- Development stage
- Phase 2
- Lead developer
- Beijing Shanqing Pharmaceutical Technology
- Administration
- Oral
01
Overview
Shenmei Pian is a traditional Chinese medicine (TCM) tablet developed by Beijing Shanqing Pharmaceutical Technology Co., Ltd. for the treatment of generalized anxiety disorder (GAD). It is specifically formulated to address the TCM syndrome of "heat disturbing the heart-mind," a pattern characterized by restlessness, irritability, and sleep disturbances. The drug underwent Phase 2 clinical evaluation in China (CTR20132599) to assess its efficacy and safety over a 6-week treatment period. As a botanical product, its therapeutic effect is derived from a combination of herbal ingredients intended to clear internal heat and soothe the spirit to alleviate symptoms of anxiety.
- Brand names
- Shenmei Pian
- Other names
- 参梅片
Beyond the preview
Go deeper on Shenmei Pian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenmei Pian.